The Adjuvant MF59 Induces ATP Release from Muscle That Potentiates Response to Vaccination

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2013 Dec 11

PMID 24324152

Citations 75

Authors

Maria Vono

Marianna Taccone

Paola Caccin

Marilena Gallotta

Giovanna Donvito

Simonetta Falzoni

Emiliano Palmieri

Michele Pallaoro

Rino Rappuoli

Francesco Di Virgilio

Ennio De Gregorio

Cesare Montecucco

Anja Seubert

Affiliations

Soon will be listed here.

Abstract

Vaccines are the most effective agents to control infections. In addition to the pathogen antigens, vaccines contain adjuvants that are used to enhance protective immune responses. However, the molecular mechanism of action of most adjuvants is ill-known, and a better understanding of adjuvanticity is needed to develop improved adjuvants based on molecular targets that further enhance vaccine efficacy. This is particularly important for tuberculosis, malaria, AIDS, and other diseases for which protective vaccines do not exist. Release of endogenous danger signals has been linked to adjuvanticity; however, the role of extracellular ATP during vaccination has never been explored. Here, we tested whether ATP release is involved in the immune boosting effect of four common adjuvants: aluminum hydroxide, calcium phosphate, incomplete Freund's adjuvant, and the oil-in-water emulsion MF59. We found that intramuscular injection is always associated with a weak transient release of ATP, which was greatly enhanced by the presence of MF59 but not by all other adjuvants tested. Local injection of apyrase, an ATP-hydrolyzing enzyme, inhibited cell recruitment in the muscle induced by MF59 but not by alum or incomplete Freund's adjuvant. In addition, apyrase strongly inhibited influenza-specific T-cell responses and hemagglutination inhibition titers in response to an MF59-adjuvanted trivalent influenza vaccine. These data demonstrate that a transient ATP release is required for innate and adaptive immune responses induced by MF59 and link extracellular ATP with an enhanced response to vaccination.

Citing Articles

Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination drives Th2-skewed response and is reduced with age.

Noureddine M, Chang L, Chang L, El Ayache F, El-Ayache F, Laghlali G Res Sq. 2025; .

PMID: 39975920 PMC: 11838721. DOI: 10.21203/rs.3.rs-5760877/v1.

Combination adjuvant improves influenza virus immunity by downregulation of immune homeostasis genes in lymphocytes.

Dollinger E, Hernandez-Davies J, Felgner J, Jain A, Hwang M, Strahsburger E Immunohorizons. 2025; 9(2).

PMID: 39849993 PMC: 11841980. DOI: 10.1093/immhor/vlae007.

System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans.

Cortese M, Hagan T, Rouphael N, Wu S, Xie X, Kazmin D Nat Immunol. 2025; 26(1):116-130.

PMID: 39747435 DOI: 10.1038/s41590-024-02036-z.

Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.

Jung M, Kim H, Choi E, Shin M, Shin S Hum Vaccin Immunother. 2024; 20(1):2317439.

PMID: 39693178 PMC: 10913723. DOI: 10.1080/21645515.2024.2317439.

Vaccine adjuvants for infectious disease in the clinic.

Goetz M, Thotathil N, Zhao Z, Mitragotri S Bioeng Transl Med. 2024; 9(4):e10663.

PMID: 39036089 PMC: 11256182. DOI: 10.1002/btm2.10663.

References

Kouzaki H, Iijima K, Kobayashi T, OGrady S, Kita H . The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol. 2011; 186(7):4375-87. PMC: 3062674. DOI: 10.4049/jimmunol.1003020. View

Kool M, Soullie T, van Nimwegen M, Willart M, Muskens F, Jung S . Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008; 205(4):869-82. PMC: 2292225. DOI: 10.1084/jem.20071087. View

Pugin J . How tissue injury alarms the immune system and causes a systemic inflammatory response syndrome. Ann Intensive Care. 2012; 2(1):27. PMC: 3488542. DOI: 10.1186/2110-5820-2-27. View

Li H, Willingham S, Ting J, Re F . Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol. 2008; 181(1):17-21. PMC: 2587213. DOI: 10.4049/jimmunol.181.1.17. View

Burnstock G . Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007; 87(2):659-797. DOI: 10.1152/physrev.00043.2006. View

Seubert A, Monaci E, Pizza M, OHagan D, Wack A . The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008; 180(8):5402-12. DOI: 10.4049/jimmunol.180.8.5402. View

Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K . DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011; 17(8):996-1002. DOI: 10.1038/nm.2403. View

Lambrecht B, Kool M, Willart M, Hammad H . Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009; 21(1):23-9. DOI: 10.1016/j.coi.2009.01.004. View

Calabro S, Tortoli M, Baudner B, Pacitto A, Cortese M, OHagan D . Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011; 29(9):1812-23. DOI: 10.1016/j.vaccine.2010.12.090. View

10.

Komoszynski M, Wojtczak A . Apyrases (ATP diphosphohydrolases, EC 3.6.1.5): function and relationship to ATPases. Biochim Biophys Acta. 1996; 1310(2):233-41. DOI: 10.1016/0167-4889(95)00135-2. View

11.

Di Virgilio F . Purinergic mechanism in the immune system: A signal of danger for dendritic cells. Purinergic Signal. 2008; 1(3):205-9. PMC: 2096539. DOI: 10.1007/s11302-005-6312-z. View

12.

Ott G, Barchfeld G, Van Nest G . Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine. 1995; 13(16):1557-62. DOI: 10.1016/0264-410x(95)00089-j. View

13.

Ferrari D, Gulinelli S, Salvestrini V, Lucchetti G, Zini R, Manfredini R . Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp Hematol. 2010; 39(3):360-74, 374.e1-5. DOI: 10.1016/j.exphem.2010.12.001. View

14.

Cintra-Francischinelli M, Pizzo P, Rodrigues-Simioni L, Ponce-Soto L, Rossetto O, Lomonte B . Calcium imaging of muscle cells treated with snake myotoxins reveals toxin synergism and presence of acceptors. Cell Mol Life Sci. 2009; 66(10):1718-28. PMC: 11115878. DOI: 10.1007/s00018-009-9053-2. View

15.

Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S . Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A. 2011; 108(27):11169-74. PMC: 3131326. DOI: 10.1073/pnas.1107941108. View

16.

Ellebedy A, Lupfer C, Ghoneim H, DeBeauchamp J, Kanneganti T, Webby R . Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc Natl Acad Sci U S A. 2011; 108(7):2927-32. PMC: 3041074. DOI: 10.1073/pnas.1012455108. View

17.

Tritto E, Mosca F, De Gregorio E . Mechanism of action of licensed vaccine adjuvants. Vaccine. 2009; 27(25-26):3331-4. DOI: 10.1016/j.vaccine.2009.01.084. View

18.

Rappuoli R, Aderem A . A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011; 473(7348):463-9. DOI: 10.1038/nature10124. View

19.

McKee A, Munks M, Marrack P . How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007; 27(5):687-90. DOI: 10.1016/j.immuni.2007.11.003. View

20.

Cintra-Francischinelli M, Caccin P, Chiavegato A, Pizzo P, Carmignoto G, Angulo Y . Bothrops snake myotoxins induce a large efflux of ATP and potassium with spreading of cell damage and pain. Proc Natl Acad Sci U S A. 2010; 107(32):14140-5. PMC: 2922586. DOI: 10.1073/pnas.1009128107. View